FAM129A, CPTAC-1623 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
FAM129A
Protein Sequence hover to view complete sequence
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MGGSASSQLD | EGKCAYIRGK | TEAAIKNFSP | YYSRQYSVAF | CNHVRTEVEQ |
| 60 | 70 | 80 | 90 | 100 |
| QRDLTSQFLK | TKPPLAPGTI | LYEAELSQFS | EDIKKWKERY | VVVKNDYAVE |
| 110 | 120 | 130 | 140 | 150 |
| SYENKEAYQR | GAAPKCRILP | AGGKVLTSED | EYNLLSDRHF | PDPLASSEKE |
| 160 | 170 | 180 | 190 | 200 |
| NTQPFVVLPK | EFPVYLWQPF | FRHGYFCFHE | AADQKRFSAL | LSDCVRHLNH |
| 210 | 220 | 230 | 240 | 250 |
| DYMKQMTFEA | QAFLEAVQFF | RQEKGHYGSW | EMITGDEIQI | LSNLVMEELL |
| 260 | 270 | 280 | 290 | 300 |
| PTLQTDLLPK | MKGKKNDRKR | TWLGLLEEAY | TLVQHQVSEG | LSALKEECRA |
| 310 | 320 | 330 | 340 | 350 |
| LTKGLEGTIR | SDMDQIVNSK | NYLIGKIKAM | VAQPAEKSCL | ESVQPFLASI |
| 360 | 370 | 380 | 390 | 400 |
| LEELMGPVSS | GFSEVRVLFE | KEVNEVSQNF | QTTKDSVQLK | EHLDRLMNLP |
| 410 | 420 | 430 | 440 | 450 |
| LHSVKMEPCY | TKVNLLHERL | QDLKSRFRFP | HIDLVVQRTQ | NYMQELMENA |
| 460 | 470 | 480 | 490 | 500 |
| VFTFEQLLSP | HLQGEASKTA | VAIEKVKLRV | LKQYDYDSST | IRKKIFQEAL |
| 510 | 520 | 530 | 540 | 550 |
| VQITLPTVQK | ALASTCKPEL | QKYEQFIFAD | HTNMIHVENV | YEEILHQILL |
| 560 | 570 | 580 | 590 | 600 |
| DETLKVIKEA | AILKKHNLFE | DNMALPSESV | SSLTDLKPPT | GSNQASPARR |
| 610 | 620 | 630 | 640 | 650 |
| ASAILPGVLG | SETLSNEVFQ | ESEEEKQPEV | PSSLAKGESL | SLPGPSPPPD |
| 660 | 670 | 680 | 690 | 700 |
| GTEQVIISRV | DDPVVNPVAT | EDTAGLPGTC | SSELEFGGTL | EDEEPAQEEP |
| 710 | 720 | 730 | 740 | 750 |
| EPITASGSLK | ALRKLLTASV | EVPVDSAPVM | EEDTNGESHV | PQENEEEEEK |
| 760 | 770 | 780 | 790 | 800 |
| EPSQAAAIHP | DNCEESEVSE | REAQPPCPEA | HGEELGGFPE | VGSPASPPAS |
| 810 | 820 | 830 | 840 | 850 |
| GGLTEEPLGP | MEGELPGEAC | TLTAHEGRGG | KCTEEGDASQ | QEGCTLGSDP |
| 860 | 870 | 880 | 890 | 900 |
| ICLSESQVSE | EQEEMGGQSS | AAQATASVNA | EEIKVARIHE | CQWVVEDAPN |
| 910 | 920 | 928 | ||
| PDVLLSHKDD | VKEGEGGQES | FPELPSEE |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for CPTAC-1623 Collapse assay details
Data source: Panorama
Official Gene Symbol
FAM129A
Peptide Sequence
VLTSEDEYNLLSDR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
125
Peptide End
138
CPTAC ID
CPTAC-1623
Peptide Molecular Mass
1,652.7893
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectSRM3
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y9 (1+) | 4.5 | 2.6 | 3.2 | 10 | 6.3 | 9.9 | 11 | 6.8 | 10.4 | 15 | 15 | 15 |
| y11 (1+) | 3.3 | 4.3 | 3.9 | 10.6 | 6.7 | 5.2 | 11.1 | 8 | 6.5 | 15 | 15 | 15 |
| y12 (1+) | 5.6 | 11.5 | 7.1 | 10.7 | 13.6 | 7.4 | 12.1 | 17.8 | 10.3 | 15 | 15 | 15 |
| sum | 2.8 | 3.6 | 3.3 | 9.5 | 7 | 7 | 9.9 | 7.9 | 7.7 | 15 | 15 | 15 |